Intuitive Surgical (NASDAQ: ISRG) experienced a sharp decline on Tuesday, with shares falling 6.2% to $381.94 by early afternoon trading. The drop erased approximately $9.1 billion in market value, as the robotic surgery leader faces increased pressure ahead of its second-quarter earnings report scheduled for Thursday.
The sell-off was triggered by HCA Healthcare's (NYSE: HCA) second-quarter results, which revealed a 2.3% decline in inpatient surgeries and a 3.4% drop in outpatient procedures. While HCA's figures do not directly correlate to Intuitive's da Vinci system utilization, they challenge the prevailing assumption that surgical demand remains robust. HCA CEO Sam Hazen expressed confidence in navigating the dynamic environment, but the operating data highlighted pressures from a higher proportion of uninsured patients and a weaker service mix.
Broader Market Impact
The negative sentiment extended beyond Intuitive, with HCA shares falling 7.6%, Stryker (NYSE: SYK) dropping 6.3%, and Medtronic (NYSE: MDT) declining 4.9%. This synchronized downturn suggests a broader reassessment of the medtech sector. Despite the decline, Intuitive's trailing price-to-earnings ratio remains elevated at 46.4x, representing a 29% premium over Stryker's 35.9x multiple and more than double Medtronic's 22.2x multiple.
Analyst Reactions
Five analysts revised their price targets for Intuitive on Monday and Tuesday, reducing the simple average by 8.8% to $543.20 from $595.40. However, this new target still sits about 42% above Tuesday's closing price, indicating that Wall Street has lowered expectations without abandoning the bullish thesis. Notable changes included Baird cutting its target from $610 to $525, TD Cowen reducing from $585 to $520, and RBC Capital Markets lowering from $650 to $600. TD Cowen cited competition, remanufactured instruments, international markets, and valuation concerns.
Key Metrics to Watch
Analysts expect Intuitive to report second-quarter revenue of approximately $2.82 billion, representing 15.6% growth, with earnings per share of $2.50, up 14.2%. This compares to first-quarter revenue growth of 23% to $2.77 billion, meaning the consensus already incorporates a significant deceleration. Investors will focus on four critical figures: da Vinci procedure growth against the annual guidance of 13.5%-15.5%, instrument revenue per procedure, da Vinci 5 placements and utilization, and adjusted gross margin.
Intuitive's recurring revenue model provides some buffer, with first-quarter recurring revenue reaching $2.4 billion or 86% of total revenue. Instrument and accessory revenue per procedure increased to approximately $1,880 from $1,780, a metric CFO Jamie Samath highlighted as reflecting the differentiated value of the da Vinci 5 system. Additionally, the company has extended the usable life of certain force-feedback instruments, potentially altering revenue timing but lowering hospital costs per procedure.
Risks and Considerations
While HCA's data may not directly translate to Intuitive's performance—da Vinci procedures grew 16% globally and 19% outside the U.S. last quarter—other headwinds persist. These include low tenders and pricing pressure in China, weak public hospital finances in Japan, softer bariatric demand, and tariff pressures. Intuitive's adjusted gross margin forecast of 67.5%-68.5% already incorporates a tariff impact equivalent to about 1% of revenue.
At 46 times trailing earnings and following a $9 billion intraday value loss, reassurance from management may not suffice. The market is demanding concrete evidence of sustained procedure growth and financial performance.
